Opioid medication and sleep-disordered breathing.

Division of Sleep Medicine, Stanford University School of Medicine, Stanford Medical Outpatient Center, 450 Broadway Street, Pavillon C, Redwood City, CA 94063-5074, USA.
The Medical clinics of North America (Impact Factor: 2.8). 05/2010; 94(3):435-46. DOI: 10.1016/j.mcna.2010.02.007
Source: PubMed

ABSTRACT There has been a growing recognition of chronic pain that may be experienced by patients. There has been a movement toward treating these patients aggressively with pharmacologic and nonpharmacologic modalities. Opioids have been a significant component of the treatment of acute pain, with their increasing use in cases of chronic pain, albeit with some controversy. In addition to analgesia, opioids have many accompanying adverse effects, particularly with regard to stability of breathing during sleep. This article reviews the existing literature on the effects of opioids on sleep, particularly sleep-disordered breathing.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Obstructive sleep apnea (OSA) is a complex medical condition that affects not only the airway but also the cardiopulmonary, endocrine, and central nervous systems. Obstructive sleep apnea can usually be identified with a focused history and physical examination and is commonly associated with obese, middle-aged men with hypertension and glucose intolerance. A high index of suspicion for OSA should arise when reports of loud snoring, nighttime arousal, and acid reflux accompanied by a history of stroke, atrial fibrillation, or congestive heart failure are elicited during a perianesthesia evaluation. Perianesthesia risk in OSA patients includes the potential for difficult airway management, cardiovascular instability, and abnormal sensitivity to sedation and analgesia. Typical doses of respiratory depressants may cause profound hypoventilation, apnea, or cardiopulmonary arrest in OSA patients. Central axial opioids and continuous intravenous opioid infusions should be avoided while nonopioid and non-centrally acting analgesics are recommended. Careful postoperative monitoring is important to preventing serious morbidity. Early identification of OSA and its comorbidities is key to developing a safe anesthesia and postoperative treatment plan.
    Critical care nursing quarterly 01/2015; 38(1):97-108. DOI:10.1097/CNQ.0000000000000044
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sleep disturbances are common in patients with cancer, occurring throughout the disease trajectory and sometimes well after treatment has concluded. Insomnia often does not occur in isolation; it may be associated with pain, fatigue, depression, and medication usage. Screening for sleep disturbances is an essential part of caring for oncologic patients. The criterion standard for nonpharmacologic treatment of insomnia in these patients is cognitive-behavioral therapy, a multimodal approach using sleep hygiene and education, stimulus control, sleep restriction, and relaxation. Exercise and complementary and integrative medicine have been studied with varying results, and no firm recommendation can be made about their efficacy.
    The Cancer Journal 09/2014; 20(5):345-351. DOI:10.1097/PPO.0000000000000066 · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sleep respiration is regulated by circadian, endocrine, mechanical and chemical factors, and characterized by diminished ventilatory drive and changes in Pao2 and Paco2 thresholds. Hypoxemia and hypercapnia are more pronounced during rapid eye movement. Breathing is influenced by sleep stage and airway muscle tone. Patient factors include medical comorbidities and body habitus. Medications partially improve obstructive sleep apnea and stabilize periodic breathing at altitude. Potential adverse consequences of medications include precipitation or worsening of disorders. Risk factors for adverse medication effects include aging, medical disorders, and use of multiple medications that affect respiration.
    Clinics in Chest Medicine 09/2014; DOI:10.1016/j.ccm.2014.06.011 · 2.17 Impact Factor